Sleep Apnea in Type 1 Diabetes

Summary

Sleep apnea syndrome is strongly associated to type 2 diabet, partly and this is partly due to obesity. Treatment of sleep apnea may improve hypertension, cardiovascular risk and in some studies diabetes status. Few data are available for type 1 diabetes but suggest that the prevalence of sleep apnea syndrome may be high. We plan to compare the prevalence of sleep apnea syndrome assessed by polysomnography in a sample of type 1 diabetic patients and a control group matched by age, gender and body mass index. The secondary objective is to determine if the presence of an autonomic neuropathy or poorly controlled diabetes (assessed by glycosylated haemoglobin) may or not contribute to the presence of sleep apnea in the diabetic group.

Conditions

• Type 1 Diabetes, Sleep Apnea Syndrome

Interventions

OTHER

Polysomnography

Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital

OTHER

Evaluation of the autonomous nervous system

blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic

OTHER

Clinical examination of the sleep

Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD

OTHER

Clinical examination of diabetology

history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire

OTHER

Biological dosages

Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test

OTHER

Electrocardiogram (ECG)

Electrocardiogram (ECG)

OTHER

Carotid echography

Carotid echography

OTHER

Blood pressure

Blood pressure

Sponsors & Collaborators

• Ministry of Health, France

  collaborator OTHER_GOV

• Assistance Publique - Hôpitaux de Paris

  lead OTHER

Principal Investigators

• Véronique Viot-Blanc, MD · Lariboisiere Hospital, APHP

• Pierre-Jean Guillausseau, MD, PhD · Lariboisiere Hopistal, APHP

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2013-09-30

Primary Completion

2019-06-30

Completion

2019-09-30

Countries

• France

Study Locations